Feline leukemia virus subgroup B (FeLV-B) is commonly associated with feline lymphosarcoma and arises through recombination between endogenous retroviral elements inherited in the cat genome and corresponding regions of the envelope (env) gene from FeLV subgroup A (FeLV-A). In vivo infectivity for FeLV-B is thought to be inefficient in the absence of FeLV-A. Proposed FeLV-A helper functions include enhanced replication efficiency, immune evasion, and replication rescue for defective FeLV-B virions. In vitro analysis of the recombinant FeLV-B-like viruses (rFeLVs) employed in this study confirmed these viruses were replication competent prior to their use in an in vivo study without FeLV-A helper virus. Eight specific-pathogenfree kittens were inoculated with the rFeLVs alone. Subsequent hematology and histology results were within normal limits, however, in the absence of detectable viremia, virus expression, or significant seroconversion, rFeLV proviral DNA was detected in bone marrow tissue of 4/4 (100%) cats at 45 weeks postinoculation (pi), indicating these rFeLVs established a limited but persistent infection in the absence of FeLV-A. Altered cell tropism was also noted. Focal infection was seen in T-cell areas of the splenic follicles in 3/4 (75%) rFeLVinfected cats analyzed, while an FeLV-A-infected cat showed focal infection in B-cell areas of the splenic follicles. Nucleotide sequence analysis of the surface glycoprotein portion of the rFeLV env gene amplified from bone marrow tissue collected at 45 weeks pi showed no sequence alterations from the original rFeLV inocula.
Feline leukemia virus (FeLV) is a naturally occurring, contagious retrovirus of the outbred domestic cat population. 13 Exogenous FeLVs are divided into subgroups A, B, and C based upon host cell receptor recognition. 28, 29 Ecotropic FeLV subgroup A (FeLV-A) is the predominant subgroup encountered in nature; it is readily transmissible, highly conserved, and has low pathogenicity. 5, 15, 33 FeLV-A also gives rise to polytropic subgroup B (FeLV-B) viruses through recombination of the FeLV-A envelope (env) gene with corresponding endogenous FeLV (enFeLV) sequences inherited in the cat genome such that, depending upon the site of recombination, a mixture of recombinant (rFeLV) genotypes can arise. 7, 17, 22, 26, 31, 32 Because FeLV-B is always isolated with FeLV-A in natural infections, 11, 14, 15, 30, 34, 35 it is thought that FeLV-A may act as a helper virus. Proposed FeLV-A helper functions in-clude enhanced replication efficiency, evading host immune surveillance, or replication rescue for defective FeLV-B variants. 13 Because of the apparent dependence on concurrent FeLV-A coinfection for FeLV-B to establish efficient in vivo infection, few studies have attempted to address the helper function of FeLV-A or the in vivo pathogenesis of FeLV-B viruses in the absence of FeLV-A. 19 In an earlier report, 30 we described the detection of rFeLV provirus in tumor DNA from naturally occurring feline thymic tumors. Three of 15 tumors (20%) harbored mutations in the vicinity of a major neutralizing epitope present in the middle of the virion surface glycoprotein (SU), an epitope highly conserved in all exogenous FeLV isolates regardless of subgroup but divergent in enFeLV clones. 6, 10, 17, 21, 30, 31 Others described a molecularly cloned natural FeLV-B variant that contained a single mutation three amino acids upstream of this epitope, rendering the FeLV-B variant resistant to neutralization by a monoclonal antibody (mAb) recognizing this same epitope. 20 In addition, our laboratory previously described the in vitro generation of a mixture of FeLV-B-like recombinants that contained a subpopulation of variants that were also resistant to neutralization by this mAb. 31 These rFeLV variants harbored enFeLV-type SU sequences encompassing this epitope and thus escaped recognition by the mAb. In another report, we presented results of an in vivo study in which 3/6 cats (50%) developed thymic lymphosarcoma following coinfection with the mixture of in vitro-generated rFeLVs and FeLV-A. 23 Nucleotide sequence analysis of rFeLV DNA isolated from the three tumor-bearing cats showed conversion from the enFeLV-type sequence to that of exogenous FeLVs within this same SU epitope. We recently described a subsequent analysis of the complete SU-encoding domain in rFeLV clones derived from one of the three cats with thymic lymphosarcoma. We found multiple nucleotide differences (19 point mutations) scattered throughout the N-terminal 80% of the SU domain, resulting in the rFeLV clones having complete sequence identity with natural FeLV-B isolates. 1 Together, these observations prompted us to consider whether such nucleotide alterations may occur in vivo without FeLV-A coinfection and whether replicationcompetent rFeLV variants harboring enFeLV-type sequence in this SU region may be able to evade host immune surveillance, thereby establishing a chronic in vivo infection in the absence of FeLV-A helper virus. We utilized the same mAb to select a subpopulation of rFeLV variants. Here, we report their in vitro characterization, the pattern of in vivo cell tropism, and results from nucleotide sequence analysis of rFeLVs recovered from cats infected with these variants in the absence of FeLV-A.
Materials and Methods

Viruses and cell lines
The parental rFeLV pool 23 contained a mixture of in vitrogenerated rFeLV species with 3Ј recombination junctions at sites A, B, E, F, and G, such that starting from the 5Ј end of the rFeLV env gene, site A recombinants harbored the least amount of enFeLV substitution and site G recombinants contained the most enFeLV sequence substitution prior to crossing over to exogenous FeLV-A-like sequence. 31 Using the C11D8 mAb, which recognizes the highly conserved MGPNL epitope in the midregion of the exogenous FeLV SU, 6,10 rFeLV variants were selected from the parental rFeLV pool, resulting in a subpopulation of variants with a majority of their SU derived from enFeLV sequence. The rFeLV pool containing 4 ϫ 10 4 50% cell culture infectious dose (CCID 50 ) was combined with 630 g C11D8 for a final mAb concentration of 210 g/ml. This mixture was incubated for 1 hour at 37 C. The 210 g/ml mAb concentration neutralized the vast majority of recombinant forms (data not shown), leaving a subpopulation of variant rFeLVs enriched for site E to site G recombinants (rFeLV/D8 variants). Virus stocks were cell culture supernatants generated from human fibrosarcoma HT1080 cells as previously described. 2 To determine whether the rFeLV/D8 pool was replication competent and to characterize its in vitro cell tropism, various human and feline cell lines were infected with the r-FeLV/D8 pool, and parallel studies were conducted with the FeLV-B/Gardner-Arnstein strain (FeLV-B/GA) 21 and the FeLV-C/Sarma strain. 24 Human HT1080 cells, feline fibroblast H927 cells, and feline 3201B T-cell lymphoma cells were employed in these studies. Replication competence was assessed using virus infectivity assays as previously described. 2 Cells were maintained for up to 4 weeks to determine potential viral infectivity. Periodically, culture supernatant was collected, clarified by centrifugation, and virus production was assessed by enzyme-linked immunosorbent assay (ELISA) as previously described. 2 The rFeLV/D8 pool was propagated in both human HT1080 cells and feline H927 cells so the H927-derived rFeLV/D8 virus stock could be assayed in parallel with the ecotropic FeLV-A/61E 5 and the HT1080-derived rFeLV/D8 virus stock could be assayed in parallel with the polytropic FeLV-B/GA 21 and FeLV-C/ Sarma 24 viruses.
In vitro neutralization studies
The in vitro neutralizing titers for the rFeLV/D8 virus stocks were evaluated in parallel with FeLV-A/61E, FeLV-B/GA, and FeLV-C/Sarma using immune sera obtained from three different cats. These cats had been challenged with an uncloned FeLV-A/Rickard plasma preparation at 20-24 weeks of age. All three immune sera had FeLV antibody titers of 1 : 512 to 1 : 1,024 by 4 weeks postinoculation (pi) as determined by indirect immunofluorescence assay (IFA). 9 Sera collected at 14 weeks pi for use in these neutralization assays were filter sterilized (0.22 m) and heated for 30 minutes at 56 C prior to use. Neutralization assays were performed by seeding cells into 96-well, flat-bottom plates using 200 cells/well 2 days prior to virus infection. On the day of infection, six to eight serial twofold predilutions of sera were made in medium to target a final neutralization range of 90-10%. Virus was also prediluted in medium to 2 CCID 50 /l, and equal volumes (0.3 ml) of serum and virus dilutions were combined to obtain a virus concentration of 1 CCID 50 /l in the final serum : virus mixture. Controls included immune sera alone (1 : 2 in medium), medium alone, and virus at 1 CCID 50 /l, which served as a positive (virus) control. A virus titration was performed concurrently with each neutralization assay to confirm the virus was actually 1 CCID 50 /l in the serum-virus mixture. The serum-virus mixtures and their controls were incubated for 1 hour at 37 C and then added to replicate wells. The remainder of the assays were performed and assessed by ELISA, as described previously. 2 ELISA values for replicate wells were averaged, and a percent neutralization (%N) was derived for each dilution using the formula mean virus control ELISA Ϫ mean test ELISA %N ϭ ϫ 100. mean virus control ELISA A neutralization curve was generated for each serum-virus mixture by plotting serum dilutions versus percent neutralization, and a 50% neutralization titer was predicted from each curve using exponential curve-fitting regression analysis.
In vivo studies
Two litters (four kittens/litter) of specific-pathogen-free (SPF) kittens were challenged intraperitoneally with the r-FeLV/D8 virus pool using 3 ϫ 10 4 focus-forming units between 4 and 8 days of age (litter No. 1, cat Nos. 1-4; litter No. 2, cat Nos. [5] [6] [7] [8] . Blood samples were collected at biweekly intervals except the first interval, which was omitted because of the animals' small size. All inoculations and specimen collections were performed under ketamine (25 mg/kg) anesthesia. Complete blood cell counts (CBCs) were determined, and viremia in whole blood smears was assessed by indirect IFA and ELISA. 11, 12 Anti-FeLV titers were determined by immunoblot and by live-cell IFA using the chronically FeLV-infected FL-74 cell line as the antigen source. 9 Litter No. 1 was euthanatized at 9 weeks pi, and complete necropsies were performed on each animal, including histopathologic evaluation. Tissue from spleen, liver, kidney, mandibular salivary gland, mesenteric lymph node, heart, urinary bladder, lung, bone marrow, thymus, small intestine, colon, pancreas, cerebrum, cerebellum, and eye were collected. Tissue samples were split, and a portion of each tissue was fixed in 10% neutral buffered formalin for histopathologic analysis. Formalin-fixed tissues were processed by standard histologic paraffin embedment, sectioned to 6 m thickness, and stained with hematoxylin and eosin prior to examination. Another portion was fixed in 100% methanol as described previously 25 prior to sectioning for immunohistochemical analysis. Methanol fixation was necessary to preserve FeLV antigen, which is otherwise denatured and not detectable following formalin fixation. Another portion of each tissue was snap frozen in liquid nitrogen for subsequent DNA/RNA analysis. Bone marrow (BM) aspirates obtained via biopsy from the proximal femur of litter No. 2 cats at 45 weeks pi were used to prepare smears for histologic examination, and the remaining portion was snap frozen.
IFA detection of viral antigens in litter No. 1 cat tissues
FeLV antigen was detected in select tissues from litter No. 1 cats using an indirect IFA technique. 25 The primary antiserum was a polyclonal goat anti-FeLV (subgroups A, B, and C), and the secondary antiserum was a fluorescein-conjugated rabbit anti-goat IgG diluted in phosphate-buffered saline solution containing 20% SPF cat serum as a blocking agent. Tissue slides were counterstained with Evan's blue.
Detection of recombinant proviral DNA in tissues of cats challenged with rFeLV/D8 variants
High-molecular-weight genomic DNA was isolated from litter No. 1 cat tissues collected at necropsy, and polymerase chain reaction (PCR) amplification was carried out using the previously described recombinant-specific primers PRB-1 and RB-17. 18 The 5Ј primer PRB-1 is enFeLV specific, and the 3Ј primer RB-17 is specific for FeLV-A. This primer set encompasses the major neutralizing epitope and all previously reported rFeLV env gene 3Ј recombination sites. 31 Genomic DNA was also extracted from BM tissues obtained via biopsy at 45 weeks pi from litter No. 2 cats, and PCR amplification was performed using the enFeLV-specific 5Ј primer RB53 and the 3Ј FeLV-A-specific primer RB-52 30 to amplify a recombinant-specific fragment (1,393 bp) . PCR products were electrophoresed on a 1% agarose gel and stained with ethidium bromide to visualize the bands.
Amplification, cloning, and nucleotide sequencing
To clone the SU portion of the recombinant env gene from the rFeLV/D8 inocula and from BM DNA collected 45 weeks pi from rFeLV/D8-infected cat No. 6, PCR amplification was performed using a 5Ј sense primer (H19) identical to a conserved sequence (GTAGACGGAGTTGCTGC) at the pol/env junction (pF6A 5877 → 5893) along with the 3Ј antisense exogenous virus-specific primer RB19, 18 which is complementary to a sequence at the 3Ј end of the transmembrane domain, yielding a 2.0-kb product. These PCR products were cloned into Invitrogen's (San Diego, CA) TA cloning vector, and screening was performed via PCR using the primer set RB56 and RB17. RB56 is an enFeLV-specific 5Ј sense primer, and RB17 is an FeLV-A-specific 3Ј antisense primer. 18, 23 To sequence the entire 1.2-kb SU-encoding region, three clones from the rFeLV/D8 inocula and three clones from BM DNA of cat No. 6 were selected, and automated sequencing was performed using fluorescence-based cycle sequencing with the ABI Prism 377 DNA Sequencer (Perkin Elmer, Foster City, CA) and the ABI Prism Dye Terminator Cycle Sequencing Kit (P/N 402080) according to the manufacturer's protocol. Cycle sequencing employed the GeneAmp 9600 thermal cycler in 25 rounds of amplification, and nucleotide sequences were resolved using 4% acrylamide gels. Nucleotide sequences were initially analyzed using the ABI Prism DNA Sequencer Analysis software (version 3.0) and subsequently assembled, analyzed, and compared with published sequences for FeLV-A/61E, 5 FeLV-B/GA, 21 FeLV-B/ST, 21 FeLV-B/RIC, 8 and CFE-6 17 using the Genejockey software.
Results
In vitro neutralizing titers determined for the rFeLV/D8 variants
In vitro neutralizing titers of the rFeLV/D8 variants were compared with exogenous FeLVs using three different immune cat sera. One series of assays employed feline H927 cells to analyze the ecotropic FeLV-A in parallel with an rFeLV/D8 virus pool propagated in the H927 cells. Another series of assays utilized human HT1080 cells to compare the polytropic FeLV-B/ GA and FeLV-C/Sarma viruses in parallel with an rFeLV/D8 virus pool prepared in human HT1080 cells. A 50% neutralizing titer was predicted from each neutralization curve, and the quality of curve fit was assessed by confirming that the coefficient of determi- nation (R 2 ) was Ͼ0.90. A summary of that analysis is presented in Table 1 . With each of the three immune sera, exogenous FeLV-A/61E and FeLV-C/Sarma were the most strongly neutralized viruses, having 50% neutralizing titers ranging from 1 : 108 to 1 : 668. The exogenous FeLV-B/GA 50% neutralizing titers ranged from 1 : 11 to 1 : 57 for the three immune sera and were comparable to the rFeLV/D8 preparations, which had 50% neutralizing titers ranging from 1 : 15 to 1 : 91. The rFeLV/D8 variants derived from human HT1080 cells consistently were more strongly neutralized (by at least twofold) than were the rFeLV/D8s derived from feline H927 cells. Analysis of the in vitro cell tropism for the rFeLV/ D8 variants indicated that these viruses were similar to the polytropic FeLV-B/GA isolate. The rFeLV/D8s and the natural FeLV-B/GA isolate grew equally well in human HT1080 cells and feline H927 fibroblasts, but only FeLV-C/Sarma was able to grow in the feline 3201B cells (data not shown). These in vitro results indicated that this subpopulation of rFeLV/D8 variants was replication competent.
Detection of rFeLV provirus in various tissues of rFeLV/D8-infected cats
High-molecular-weight genomic DNA was isolated from select snap-frozen litter No. 1 tissues, biopsied samples of BM aspirates from litter No. 2 cats, and from the in vitro-propagated rFeLV/D8 inocula. These DNA samples were then analyzed by recombinant-specific PCR amplification. In litter No. 1 cats, PCR results demonstrated a product of expected size (ϳ870 bp) in most tissues analyzed ( Table 2 ). Spleen and liver from all four cats were positive for this PCR product; thymus and BM from three of four cats and lymph node tissues from two of three cats tested were also positive for this PCR product. However, the amount of rFeLV proviral sequence present in the various tissue DNAs was apparently quite low; to see a band in the gel using 20% of the total PCR product, 50 PCR amplification cycles were required.
Blood samples were collected initially at biweekly intervals, and later at monthly intervals, from litter No. 2 cat Nos. 5-8 and analyzed for FeLV antigen and anti-FeLV seroconversion. During the 45-week observation period, all four animals demonstrated a delayed (Ͼ10 weeks pi) low-level FeLV antibody response (Յ64), but none tested positive for FeLV antigens. PCR amplification of genomic DNA isolated from BM aspirates from these cats at 45 weeks pi showed a recombinant-specific product of expected size (1.39 kb). A representative PCR experiment illustrating this result is presented in Fig. 1 . Although this rFeLV proviral PCR product was present in BM DNA from all four rFeLV/D8-infected litter No. 2 cats at 45 weeks pi, none had detectable rFeLV proviral DNA in peripheral blood lymphocytes (buffy coats) at 5 weeks pi or 32 weeks pi as measured by PCR, and none demonstrated rFeLV expression in BM at 45 weeks pi as measured by nested reverse transcription-PCR (RT-PCR) analysis (data not shown).
Immunohistochemical analysis demonstrates altered in vivo cell tropism for rFeLV/D8-infected cats
Tissues collected from litter No. 1 cats were analyzed for histologic lesions and viral antigen expression. Histologically, all four cats had prominent white pulp in the spleen and reactive lymph nodes. One cat showed lymph node medullary hypoplasia. The thymus was well developed, with beginning signs of involution in one cat. Gross examination of the pancreas in these cats showed a more globular appearance than expected for their age (data not shown); however, microscopic examination of the pancreatic tissues revealed no lesions or structural abnormalities. Gross and microscopic examinations of kidney, heart, urinary bladder, lung, stomach, small intestine, colon, cerebrum, cerebellum, and eye tissue samples did not reveal any abnormalities (data not shown). Tissues from litter No. 1 cats were immunostained using indirect IFA and were positive for FeLV antigen expression. Three of four rFeLV/D8-infected cats showed FeLV antigen in the spleen primarily in the marginal zone (T-cell areas) surrounding some splenic follicles (Fig.  2) . By comparison, spleen tissue from a cat infected with FeLV-A/Rickard showed very strong reactivity in the follicle germinal center (B-cell area) ( Fig. 3) . Staining was lacking in the spleen of an uninfected SPF kitten (Fig. 4) . Single mesenteric lymph nodes derived from three of four rFeLV/D8-infected litter No. 1 cats displayed antigen-positive cells scattered throughout the paracortical region and cortex, and one of four rFeLV/D8-infected litter No. 1 cats showed staining of duct epithelium in the mandibular salivary gland (Fig. 5) .
A comparison of the CBC results between litter No. 1 and litter No. 2 cats at 9 weeks pi was performed. The CBCs at 9 weeks pi for litter No. 1 cats were within normal limits for three of four cats (75%), with the fourth showing slightly elevated lymphocyte counts of 10.2 ϫ 10 6 /ml. The CBCs for litter No. 2 cats at 9 weeks pi showed slightly elevated lympho-cyte counts of 9.3, 9.6, and 11.4 ϫ 10 6 /ml, respectively, in three of four cats (75%), but the fourth cat had CBC values within normal limits. Smears prepared from BM aspirates collected via biopsy at 45 weeks pi from litter No. 2 cats showed myeloid : erythroid ratios averaging approximately 1.5 : 1, orderly maturation of both red and white cells, and were FeLV antigen negative by IFA analysis (data not shown). Overall BM tissue appeared to be within normal parameters.
Nucleotide sequence analysis demonstrates the in vivo-derived rFeLV sequence was unchanged from the parental rFeLV/D8 sequence
As expected, nucleotide sequence analysis of clones derived from the rFeLV/D8 inocula indicated that the majority of the SU portion of the env gene was identical to the parental enFeLV/CFE-6 sequence 17 (Fig.  6 ). The env gene recombination structural motifs have been determined for each of the three reported natural FeLV-B isolates, FeLV-B/GA, FeLV-B/ST, and FeLV-B/RIC, including the multiple nucleotide differences conserved in the SU regions for the three FeLV-B isolates but divergent in the reported sequence for the endogenous FeLV clone CFE-6 ( Fig. 6 ). When rFeLV clones derived from BM DNA of cat No. 6 at 45 weeks pi were also sequenced and analyzed, it was clear that the nucleotide sequences for the in vivoderived rFeLVs were unchanged from those of the rFeLV/D8 inocula. None of these in vivo-derived r-FeLV clones harbored any of the multiple nucleotide differences seen in natural FeLV-B isolates. 
Discussion
Consistent with early epidemiologic surveys, 27 the in vitro neutralization assays reported here demonstrated that exogenous FeLV-A and FeLV-C were the most strongly neutralized viruses in the presence of the immune sera. In contrast, both the exogenous FeLV-B/ GA isolate and the rFeLV/D8 variants were only weakly neutralized, having 50% neutralization titers considerably less than titers observed with the FeLV-A and FeLV-C viruses. It is currently unclear why the rFeLV/D8 variants derived from human HT1080 cells were more strongly neutralized than the rFeLV/D8 variants derived from feline H927 cells. It is possible some neutralizing activity in the cat immune sera may be directed against human antigen(s) incorporated into the rFeLV/D8 viral envelope when the maturing virion buds through the human HT1080 host cell membrane. Results from in vitro cell tropism studies also showed that the subpopulation of rFeLV/D8 variants behaved comparably to the natural FeLV-B/GA isolate, indicating the rFeLV/D8 variants utilized in this study were replication competent. Fig. 6 . Schematic comparison between env nucleotide sequences for the rFeLV/D8 inocula and in vivo-derived clones from rFeLV/D8-infected cat No. 6 from litter No. 2 at 45 weeks pi. Numbering for the FeLV-A/61E sequence is as reported, 5 and indicated deletions within the FeLV-A/61E sequence are relative to the enFeLV/CFE-6 published sequence. 17 Small vertical lines within the diagrams for the reported FeLV-B isolates, FeLV-B/GA, 21 FeLV-B/ST, 21 and FeLV-B/RIC 8 indicate nucleotide alterations relative to enFeLV/CFE-6. 1, 17 Recombination junction sites A through G are included for reference, 31 and the question mark at the left in the FeLV-B/ST diagram indicates that its 5Ј recombination junction has not been determined.
During the in vivo phase of this study, the initial litter of kittens (litter No. 1) failed to show any evidence of viral infection during the interval in which we normally detect viral antigens or seroconversion in animals. However, once the animals were euthanatized and postmortem analyses were performed on various tissues, results indicated a limited and atypical FeLV infection. Recombinant proviral DNA was detected via PCR in a variety of litter No. 1 cat tissues in spite of the fact that gross and microscopic examinations revealed no lesions related to virus infection and the absence of detectable viremia and with minimal seroconversion in these rFeLV/D8-infected cats. Altered in vivo cell tropism was also found. The rFeLV/D8 variants appeared to preferentially infect T-cell areas (marginal zones) of the splenic follicles, albeit weakly, whereas FeLV-A/Rickard demonstrated strong antigen expression primarily in B-cell areas (germinal centers) of the splenic follicles. We and others have repeatedly found strong FeLV antigen expression in the germinal centers of splenic follicles in FeLV-A-infected cats. 11, 12, 25 The weak expression of FeLV antigen in the marginal zones (T-cell areas) of the splenic follicles in cats infected with the rFeLV/D8 variants alone suggests that this variant has altered tropism and/or expression patterns. The expression of FeLV antigen in the salivary gland from one of the rFeLV/D8-infected cats also suggests a possible mechanism for transmission of this recombinant FeLV variant. FeLV is efficiently transmitted horizontally, and the primary mode of transmission for FeLV is through saliva and nasal secretions. 13, 26 In natural FeLV infection, FeLV is spread by ingestion, so that viral transmission can take place through social behaviors such as mutual grooming, sharing of food, and biting. Our detection of FeLV antigen in the salivary gland of at least one of the four rFeLV/D8-infected cats from litter No. 1 indicates that this recombinant variant may be capable of horizontal transmission. However, because of its apparent low expression level, this recombinant variant would likely have very poor transmission efficiency.
The lack of detectable antigens in the blood of the rFeLV/D8-infected cats may also be due to low virus expression or perhaps to selection of a virus phenotype that is highly cell associated. Inefficient virus replication and the cell-associated phenotype may also account for the lack of detectable antibody to FeLV. The altered cell tropism may be a consequence of inefficient rFeLV infection in the absence of FeLV-A. It is possible that recombinants may preferentially infect T cells initially and, in the presence of FeLV-A, subsequently spread to other cell types. However, in the ab-sence of FeLV-A a limited infection leads to rFeLVs being restricted to T-cell areas. Altered cell tropism associated with rFeLVs has been previously described by our laboratory. We demonstrated immunostaining of endothelial cells derived from the central nervous system of cats infected with a mixture of FeLV-C recombinants, but brain tissue of cats infected with parental FeLV-C alone showed no such staining. 3, 26 Because there is ample evidence that cell receptor choice is primarily dictated by the N-terminus of the viral SU, 26 the altered cell tropism for these recombinants probably is mediated by the enFeLV-derived portion of the SU. Taken together, our results suggest that rFeLVs, whether FeLV-C derived or FeLV-B-like, in the absence of FeLV-A helper virus, can demonstrate altered in vivo cell tropism.
Based upon our results from litter No. 1 cats and considering the possibility of litter bias, a second challenge study was initiated using the litter No. 2 kittens, and the protocol was extended to monitor the animals for more than 6 months. Over the 45-week timecourse, all four animals demonstrated a minimal and delayed FeLV antibody response without detectable viremia. Hematologic profiles for the four cats were unremarkable. However, PCR analysis of genomic DNA isolated from BM aspirates obtained at 45 weeks pi indicated the presence of recombinant provirus. Subsequent analysis by nested RT-PCR for rFeLV expression in the BM was negative. When nucleotide sequences for rFeLV clones derived from rFeLV/D8infected cat No. 6 were compared with sequences from parental rFeLV/D8 clones, the in vivo-derived sequences were unchanged. These results are in contrast to those obtained in another recent study in which multiple nucleotide differences were found scattered throughout the SU-encoding env region in rFeLV clones recovered from cats coinfected with FeLV-A and a mixture of in vitro-generated rFeLVs. 1 None of these nucleotide differences were noted in the in vivoderived rFeLV clones in the absence of FeLV-A. Together, these results indicate that FeLV-A coinfection serves to enhance rFeLV replication efficiency, ultimately leading to the emergence of random genotypic mutations within the mixture of rFeLV variants followed by selective pressures promoting the proliferation of mutant rFeLV genomes harboring advantageous mutations (i.e., FeLV-B-like sequence). This interpretation is commensurate with the current paradigm for retroviral genetic diversity, in which sufficient numbers of genomes must be produced to ensure the emergence of adaptive mutations. 4, 16 The data presented here indicate that replicationcompetent rFeLV variants could establish a limited in vivo infection in the absence of FeLV-A by evading host immune surveillance and exhibiting altered cell tropism. However, in the absence of efficient in vivo viral replication, such as occurs in the presence of FeLV-A, those nucleotide alterations that give rise to conversion of rFeLV env sequences to those of natural FeLV-B isolates were not observed.
